ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Oct 2018
Last Updated on 01 Oct 2018
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Sevelamer carbonate 800 mg tablet for the treatment of hyperphosphataemia in patients with chronic kidney disease who:
    • have persistent hyperphosphataemia despite optimising treatment with calcium-based phosphate binders; or
    • cannot tolerate calcium-based phosphate binders due to hypercalcaemia.

Subsidy status
Sevelamer carbonate 800 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.
MAF assistance does not apply to lanthanum carbonate 500 mg, 750 mg, and 1000 mg tablets.

Lanthanum and sevelamer for hyperphosphataemia in CKD (1 Oct 2018)